Daohong Zhou
Affiliations: | Medical University of South Carolina, Charleston, SC, United States |
Area:
Molecular Biology, Cell Biology, PathologyGoogle:
"Daohong Zhou"
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Kang JW, Zhan Z, Ji G, et al. (2021) PUMA facilitates EMI1-promoted cytoplasmic Rad51 ubiquitination and inhibits DNA repair in stem and progenitor cells. Signal Transduction and Targeted Therapy. 6: 129 |
Faust HJ, Zhang H, Han J, et al. (2020) IL-17 and immunologically induced senescence regulate response to injury in osteoarthritis. The Journal of Clinical Investigation |
Kim HN, Xiong J, MacLeod RS, et al. (2020) Osteocyte RANKL is required for cortical bone loss with age and is induced by senescence. Jci Insight |
Acklin S, Zhang M, Du W, et al. (2020) Depletion of senescent-like neuronal cells alleviates cisplatin-induced peripheral neuropathy in mice. Scientific Reports. 10: 14170 |
Vara N, Liu Y, Yan Y, et al. (2020) Sustained fetal hematopoiesis causes juvenile death from leukemia: evidence from a dual-age-specific mouse model. Blood Advances. 4: 3728-3740 |
He Y, Khan S, Huo Z, et al. (2020) Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies. Journal of Hematology & Oncology. 13: 103 |
He Y, Koch R, Budamagunta V, et al. (2020) DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas. Journal of Hematology & Oncology. 13: 95 |
Zhang X, He Y, Zhang P, et al. (2020) Discovery of IAP-recruiting BCL-X PROTACs as potent degraders across multiple cancer cell lines. European Journal of Medicinal Chemistry. 199: 112397 |
He Y, Zhang X, Chang J, et al. (2020) Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity. Nature Communications. 11: 1996 |
Zhang X, Thummuri D, Liu X, et al. (2020) Discovery of PROTAC BCL-X degraders as potent anticancer agents with low on-target platelet toxicity. European Journal of Medicinal Chemistry. 192: 112186 |